TY - JOUR
T1 - Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay
AU - The Genotype to Phenotype Japan (G2P-Japan) Consortium
AU - Nasser, Hesham
AU - Shimizu, Ryo
AU - Ito, Jumpei
AU - Matsuno, Keita
AU - Nao, Naganori
AU - Sawa, Hirofumi
AU - Kishimoto, Mai
AU - Tanaka, Shinya
AU - Tsuda, Masumi
AU - Wang, Lei
AU - Oda, Yoshikata
AU - Kato, Marie
AU - Ferdous, Zannatul
AU - Mouri, Hiromi
AU - Shishido, Kenji
AU - Fukuhara, Takasuke
AU - Tamura, Tomokazu
AU - Suzuki, Rigel
AU - Ito, Hayato
AU - Yamasoba, Daichi
AU - Kimura, Izumi
AU - Misawa, Naoko
AU - Uriu, Keiya
AU - Kosugi, Yusuke
AU - Fujita, Shigeru
AU - Suganami, Mai
AU - Chiba, Mika
AU - Yoshimura, Ryo
AU - Nakagawa, So
AU - Wu, Jiaqi
AU - Takaori-Kondo, Akifumi
AU - Shirakawa, Kotaro
AU - Nagata, Kayoko
AU - Kazuma, Yasuhiro
AU - Nomura, Ryosuke
AU - Horisawa, Yoshihito
AU - Tashiro, Yusuke
AU - Kawai, Yugo
AU - Irie, Takashi
AU - Kawabata, Ryoko
AU - Begum, MST Monira
AU - Takahashi, Otowa
AU - Ichihara, Kimiko
AU - Ueno, Takamasa
AU - Motozono, Chihiro
AU - Toyoda, Mako
AU - Tanaka, Yuri L.
AU - Hashiguchi, Takao
AU - Suzuki, Tateki
AU - Tabata, Kaori
N1 - Funding Information:
We would like to thank all members belonging to The Genotype to Phenotype Japan (G2P-Japan) Consortium. We thank Dr. Kenzo Tokunaga (National Institute for Infectious Diseases, Japan) and Dr. Jin Gohda (The University of Tokyo, Japan) for providing reagents. We also thank Ms. Kazuko Kitazato and Haruyo Hasebe for their excellent assistance. This study was supported in part by AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP21fk0108465 to A.S.; JP21fk0108146 and JP22fk0108146 to K.S.; JP20fk0108413 to K.S. and T.I.; JP20fk0108451 to G2P-Japan Consortium, A.S. K.S. and T.I.; JP21fk0108574 to H.N.; and JP21fk0108494 to G2P-Japan Consortium, K.S. and T.I.); AMED Research Program on HIV/AIDS (JP21fk0410033, JP22fk0410033, and JP22fk0410047 to A.S.; JP21fk0410039 and JP22fk0410039 to K.S.; and JP22fk0410055 to T.I.); AMED CRDF Global Grant (JP21jk0210039 and JP22jk0210039 to A.S.); AMED Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0325009 and JP22wm0325009 to A.S.); JST A-STEP (JPMJTM20SL to T.I.); JST SICORP (e-ASIA) (JPMJSC20U1 to K.S.); JST SICORP (JPMJSC21U5 to K.S.), JST CREST (JPMJCR20H4 to K.S.); JSPS KAKENHI Grant-in-Aid for Scientific Research C (19K06382 to A.S. and 22K07103 to T.I.); JSPS KAKENHI Grant-in-Aid for Scientific Research B (18H02662 and 21H02737 to K.S.); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (22K16375 to H.N.); JSPS Fund for the Promotion of Joint International Research (Fostering Joint International Research) (18KK0447 to K.S.); JSPS Core-to-Core Program (A. Advanced Research Networks) (JPJSCCA20190008 to K.S.); JSPS Leading Initiative for Excellent Young Researchers (LEADER) (to T.I.); The Tokyo Biochemical Research Foundation (to K.S.); Takeda Science Foundation (to T.I.); Mitsubishi Foundation (to T.I.); Shin-Nihon Foundation of Advanced Medical Research (to T.I.); Waksman Foundation of Japan (to T.I.); a Grant for Joint Research Projects of the Research Institute for Microbial Diseases, Osaka University (to A.S.); an intramural grant from Kumamoto University COVID-19 Research Projects (AMABIE) (to T.I.); and Intercontinental Research and Educational Platform Aiming for Eradication of HIV/AIDS (to T.I.). H.N. R.S. A.S. K.S. and T.I. performed the experiments. H.N. A.S. K.S. and T.I. designed the experiments and interpreted the results. J.I. and T.I. performed the statistical analyses. H.N. and T.I. wrote the original manuscript. All authors reviewed and proofread the manuscript. The Genotype to Phenotype Japan (G2P-Japan) Consortium contributed to the project administration. The authors declare no competing interests.
Funding Information:
This study was supported in part by AMED Research Program on Emerging and Re-emerging Infectious Diseases ( JP21fk0108465 to A.S.; JP21fk0108146 and JP22fk0108146 to K.S.; JP20fk0108413 to K.S. and T.I.; JP20fk0108451 to G2P-Japan Consortium, A.S., K.S., and T.I.; JP21fk0108574 to H.N.; and JP21fk0108494 to G2P-Japan Consortium, K.S., and T.I.); AMED Research Program on HIV/AIDS ( JP21fk0410033 , JP22fk0410033 , and JP22fk0410047 to A.S.; JP21fk0410039 and JP22fk0410039 to K.S.; and JP22fk0410055 to T.I.); AMED CRDF Global Grant ( JP21jk0210039 and JP22jk0210039 to A.S.); AMED Japan Program for Infectious Diseases Research and Infrastructure ( JP21wm0325009 and JP22wm0325009 to A.S.); JST A-STEP ( JPMJTM20SL to T.I.); JST SICORP (e-ASIA) ( JPMJSC20U1 to K.S.); JST SICORP ( JPMJSC21U5 to K.S.), JST CREST ( JPMJCR20H4 to K.S.); JSPS KAKENHI Grant-in-Aid for Scientific Research C ( 19K06382 to A.S. and 22K07103 to T.I.); JSPS KAKENHI Grant-in-Aid for Scientific Research B ( 18H02662 and 21H02737 to K.S.); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists ( 22K16375 to H.N.); JSPS Fund for the Promotion of Joint International Research (Fostering Joint International Research) ( 18KK0447 to K.S.); JSPS Core-to-Core Program (A. Advanced Research Networks) ( JPJSCCA20190008 to K.S.); JSPS Leading Initiative for Excellent Young Researchers (LEADER) (to T.I.); The Tokyo Biochemical Research Foundation (to K.S.); Takeda Science Foundation (to T.I.); Mitsubishi Foundation (to T.I.); Shin-Nihon Foundation of Advanced Medical Research (to T.I.); Waksman Foundation of Japan (to T.I.); a Grant for Joint Research Projects of the Research Institute for Microbial Diseases, Osaka University (to A.S.); an intramural grant from Kumamoto University COVID-19 Research Projects (AMABIE) (to T.I.); and Intercontinental Research and Educational Platform Aiming for Eradication of HIV/AIDS (to T.I.).
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/12/16
Y1 - 2022/12/16
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein mediates membrane fusion between the virus and the target cells, triggering viral entry into the latter. Here, we describe a SARS-CoV-2 spike-protein-mediated membrane fusion assay using a dual functional split reporter protein to quantitatively monitor the fusion kinetics of the viral and target cell membranes in living cells. This approach can be applied in various cell types, potentially predicting the pathogenicity of newly emerging variants. For complete details on the use and execution of this protocol, please refer to Kimura et al. (2022b), Kimura et al. (2022c), Motozono et al. (2021), Saito et al. (2022a), Saito et al. (2022b), Suzuki et al. (2022), and Yamasoba et al. (2022).
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein mediates membrane fusion between the virus and the target cells, triggering viral entry into the latter. Here, we describe a SARS-CoV-2 spike-protein-mediated membrane fusion assay using a dual functional split reporter protein to quantitatively monitor the fusion kinetics of the viral and target cell membranes in living cells. This approach can be applied in various cell types, potentially predicting the pathogenicity of newly emerging variants. For complete details on the use and execution of this protocol, please refer to Kimura et al. (2022b), Kimura et al. (2022c), Motozono et al. (2021), Saito et al. (2022a), Saito et al. (2022b), Suzuki et al. (2022), and Yamasoba et al. (2022).
UR - http://www.scopus.com/inward/record.url?scp=85140357546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140357546&partnerID=8YFLogxK
U2 - 10.1016/j.xpro.2022.101773
DO - 10.1016/j.xpro.2022.101773
M3 - Article
C2 - 36313538
AN - SCOPUS:85140357546
VL - 3
JO - STAR Protocols
JF - STAR Protocols
SN - 2666-1667
IS - 4
M1 - 101773
ER -